<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41813">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01833624</url>
  </required_header>
  <id_info>
    <org_study_id>2012-A00078-35</org_study_id>
    <nct_id>NCT01833624</nct_id>
  </id_info>
  <brief_title>Efficiency of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula</brief_title>
  <acronym>NUTRI_REA</acronym>
  <official_title>Efficiency and Tolerance of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula in the Critically Ill Patient : a Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nestlé Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An early and efficient enteral nutritional support could improve the clinical outcomes of
      brain injured critically ill patients. Gastrointestinal feeding intolerance defined as an
      increased gastric residual volume frequently occurs in these patients.

      Previous experimental studies have suggested that a small-peptide enteral feeding formula
      could promote the gastric emptying compared to a whole-protein formula. An improved
      gastrointestinal tolerance of enteral nutrition should allow a rapid increase in the daily
      caloric intake and enhance nutritional support of brain injured critically ill patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-labelled prospective randomized trial aims to compare 2 groups of patients: the
      Study Group and the Control Group. The randomization process will concern the allocation of
      the type of enteral feeding formula administered for nutritional support: Peptamen® AF in
      the Study Group, and Sondalis® HP in the Control Group. 2 centers are involved in this
      study.

      Each patient admitted in the critical care unit will be assessed for eligibility. After
      written informed consent is obtained from relatives, patient without any exclusion criteria
      will be included in the study.

      The allocation of the type of enteral nutritional feeding formula will be randomized after
      inclusion.

      Enteral nutrition according to the randomization group will start within the 48 hours of
      admission and up to 10 days, if requested. Beyond the 10th day, all patients will receive
      standard enteral nutrition formula.

      After inclusion, data regarding efficacy and tolerance will be assessed daily up to day 10.

      Mortality and outcome will be assessed at day 28 and at day 60.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>the nutritional efficacy of a small-peptide (Peptamen AF®) to that of a whole-protein (Sondalis HP®) enteral feeding formula in traumatic and non-traumatic brain injured critically ill patients</measure>
    <time_frame>Day3 to Day5</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the nutritional efficacy of a small-peptide (Peptamen AF®) to that of a whole-protein (Sondalis HP®) enteral feeding formula in traumatic and non-traumatic brain injured critically ill patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>impact on morbidity and mortality of a small-peptide (Peptamen AF®) to that of a whole-protein (Sondalis HP®) enteral feeding formula.</measure>
    <time_frame>Day 10</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Traumatic and/or Non-traumatic Brain Injury</condition>
  <condition>Critically Ill</condition>
  <arm_group>
    <arm_group_label>Sondalis® HP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Control Group that will receive Sondalis ® HP (a whole-peptide formula).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peptamen® AF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, patients have enteral nutrition with Peptamen® AF</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Peptamen® AF</intervention_name>
    <description>Comparison of two types of enteral nutrition feeding: Peptamen® AF and Sondalis® HP</description>
    <arm_group_label>Sondalis® HP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sondalis® HP</intervention_name>
    <arm_group_label>Peptamen® AF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission in our surgical critical care unit.

          -  Traumatic brain injury.

          -  Non-traumatic brain injury: stroke, intracranial and/or subarachnoid hemorrhage,
             subdural and/or extradural hematoma.

          -  Expected duration of mechanical ventilation &gt; 48 hours.

        Exclusion Criteria:

          -  Abdominal surgery in the previous 30 days.

          -  Pregnancy.

          -  Breast-feeding.

          -  Hemodynamic instability defined as infusion of norepinephrine &gt; 3 mg/h, or
             epinephrine &gt; 1 mg/h, or as increasing needs in vasopressive or inotropic drugs.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Blasco</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Sophie BALON</last_name>
    <phone>+3381668675</phone>
    <email>annesophie.balon@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Surgical Critical Care Unit, CHRU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Sophie BALON</last_name>
      <phone>+3381668675</phone>
      <email>annesophie.balon@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gilles Blasco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 16, 2013</lastchanged_date>
  <firstreceived_date>February 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire de Besancon</investigator_affiliation>
    <investigator_full_name>Anne-Sophie BALON</investigator_full_name>
    <investigator_title>Docteur Anne-Sophie BALON</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
